List of Excipients in API ACAMPROSATE CALCIUM
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ACAMPROSATE CALCIUM
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | CELLULOSE, MICROCRYSTALLINE | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | CROSPOVIDONE | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | MAGNESIUM SILICATE | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | MAGNESIUM STEARATE | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | PROPYLENE GLYCOL | |
| Carilion Materials Management | CAMPRAL | acamprosate calcium | 68151-4760 | SILICON DIOXIDE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing ACAMPROSATE CALCIUM
Detailed excipient profiles for ACAMPROSATE CALCIUM
Excipient focus: AMMONIA
ACAMPROSATE CALCIUM drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing AMMONIA
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ACAMPROSATE CALCIUM drug variants containing CELLULOSE, MICROCRYSTALLINE
ACAMPROSATE CALCIUM drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ACAMPROSATE CALCIUM drug variants containing CROSPOVIDONE
ACAMPROSATE CALCIUM drug variants not containing CROSPOVIDONE
Excipient focus: FERROSOFERRIC OXIDE
ACAMPROSATE CALCIUM drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing FERROSOFERRIC OXIDE
Excipient focus: GLYCERYL DIBEHENATE
ACAMPROSATE CALCIUM drug variants containing GLYCERYL DIBEHENATE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing GLYCERYL DIBEHENATE
Excipient focus: HYPROMELLOSE
ACAMPROSATE CALCIUM drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
ACAMPROSATE CALCIUM drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | acamprosate calcium | 0093-5352 |
| AvKARE | acamprosate calcium | 42291-104 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing HYPROMELLOSE 2910
Excipient focus: MAGNESIUM SILICATE
ACAMPROSATE CALCIUM drug variants containing MAGNESIUM SILICATE
ACAMPROSATE CALCIUM drug variants not containing MAGNESIUM SILICATE
Excipient focus: MAGNESIUM STEARATE
ACAMPROSATE CALCIUM drug variants containing MAGNESIUM STEARATE
ACAMPROSATE CALCIUM drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM TRISILICATE
ACAMPROSATE CALCIUM drug variants containing MAGNESIUM TRISILICATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | acamprosate calcium | 0093-5352 |
| AvKARE | acamprosate calcium | 42291-104 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing MAGNESIUM TRISILICATE
Excipient focus: METHACRYLIC ACID
ACAMPROSATE CALCIUM drug variants containing METHACRYLIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing METHACRYLIC ACID
Excipient focus: METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
ACAMPROSATE CALCIUM drug variants containing METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| Major Pharmaceuticals | acamprosate calcium | 0904-7213 |
| Marlex Pharmaceuticals Inc | acamprosate calcium | 10135-636 |
| AvKARE | acamprosate calcium | 42291-104 |
| American Health Packaging | acamprosate calcium | 60687-121 |
| Carilion Materials Management | acamprosate calcium | 68151-4760 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
Excipient focus: METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
ACAMPROSATE CALCIUM drug variants containing METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Excipient focus: METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
ACAMPROSATE CALCIUM drug variants containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | acamprosate calcium | 0093-5352 |
| Glenmark Pharmaceuticals Inc USA | acamprosate calcium | 68462-435 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Excipient focus: POLYETHYLENE GLYCOL 400
ACAMPROSATE CALCIUM drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | acamprosate calcium | 0093-5352 |
| AvKARE | acamprosate calcium | 42291-104 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing POLYETHYLENE GLYCOL 400
Excipient focus: POLYETHYLENE GLYCOL 8000
ACAMPROSATE CALCIUM drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | acamprosate calcium | 0093-5352 |
| AvKARE | acamprosate calcium | 42291-104 |
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing POLYETHYLENE GLYCOL 8000
Excipient focus: POVIDONE
ACAMPROSATE CALCIUM drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Major Pharmaceuticals | acamprosate calcium | 0904-7213 |
| American Health Packaging | acamprosate calcium | 60687-121 |
| Glenmark Pharmaceuticals Inc USA | acamprosate calcium | 68462-435 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing POVIDONE
Excipient focus: POVIDONE K30
ACAMPROSATE CALCIUM drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Marlex Pharmaceuticals Inc | acamprosate calcium | 10135-636 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing POVIDONE K30
Excipient focus: POVIDONE K90
ACAMPROSATE CALCIUM drug variants containing POVIDONE K90
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing POVIDONE K90
Excipient focus: PROPYLENE GLYCOL
ACAMPROSATE CALCIUM drug variants containing PROPYLENE GLYCOL
ACAMPROSATE CALCIUM drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
ACAMPROSATE CALCIUM drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing SHELLAC
Excipient focus: SILICON DIOXIDE
ACAMPROSATE CALCIUM drug variants containing SILICON DIOXIDE
ACAMPROSATE CALCIUM drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
ACAMPROSATE CALCIUM drug variants containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing SODIUM BICARBONATE
Excipient focus: SODIUM LAURYL SULFATE
ACAMPROSATE CALCIUM drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc | acamprosate calcium | 68382-569 |
| Zydus Lifesciences Limited | acamprosate calcium | 70771-1057 |
| >Company | >Ingredient | >NDC |
ACAMPROSATE CALCIUM drug variants not containing SODIUM LAURYL SULFATE
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
ACAMPROSATE CALCIUM drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
ACAMPROSATE CALCIUM drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | acamprosate calcium enteric-coated | 0378-6333 |
| Mylan Institutional Inc | acamprosate calcium enteric-coated | 51079-241 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
ACAMPROSATE CALCIUM drug variants containing TALC
ACAMPROSATE CALCIUM drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
